Cefpodoxime (CPD)

Cefpodoxime is an oral third generation cephalosporin antibiotic. It is active against most Gram positive and Gram negative organisms. Notable exceptions include Pseudomonas aeruginosa, Enterococcus, and Bacteroides fragilis. Cefpodoxime inhibits cell wall synthesis by inhibiting final transpeptidation step of peptidoglycan synthesis in cell walls. It is indicated in Community Acquired Pneumonia, Uncomplicated Skin and Skin Structure Infections and Uncomplicated Urinary Tract Infections. Currently, certain bacteria, such as Citrobacter amalonaticus, Enterobacter intermedius and Listeria innocua are resistant toward Cefpodoxime. While Haemophilus influenzae, Neisseria gonorrhoeae, Salmonella Agona and Shigella boydii are susceptible to Cefpodoxime. Some bacteria, such as Bacteroides bivius, Clostridium difficile, Escherichia coli and Klebsiella pneumonia have developed resistance towards Cefpodoxime to varying degrees.